PD-L1 protein expression and CD274 mRNA in non-small cell lung cancer (NSCLC) are higher than in healthy lung tissues. Comparison of PD-L1 protein expression levels detected by immunohistochemistry (IHC) (A) in different subtypes of NSCLC (* p = 0.0074).

Oct 31, 2024 · This study aimed to investigate the prognostic value of PD-L1 in patients with NSCLC receiving neoadjuvant immune checkpoint inhibitor plus chemotherapy (CT).

In NSCLC, PD-L1 expression reported as the percentage of viable tumor cells showing membranous staining for PD-L1 at immunohistochemistry (tumor proportion score, TPS) is a predictive biomarker of response to ICIs targeting PD-1 or PD-L1.

Nov 10, 2016 · Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non–small-cell lung cancer (NSCLC), with increased activity in tumors...

Aug 4, 2017 · It is expressed on T cells, B cells, and natural killer (NK) cells and binds to its ligands PD-L1 and PD-L2 (1). Expression of PD-L1 rarely occurs on normal tissues but is prevalent on antigen presenting cells (APCs) and tumor cells in numerous solid malignancies including NSCLC.

Sep 30, 2020 · Atezolizumab treatment resulted in significantly longer overall survival than platinum-based chemotherapy among patients with NSCLC with high PD-L1 expression, regardless of histologic type.

Feb 12, 2025 · We included phase 3 randomized clinical trials (RCTs) from 2022 to 2024 that reported 5-year overall survival (OS) or progression-free survival (PFS) of patients with advanced or metastatic PD-L1–negative NSCLC who received an ICI-containing regimen compared with chemotherapy alone.

Immunotherapy has revolutionized the diagnosis and treatment model for patients with advanced non-small cell lung cancer (NSCLC). Numerous clinical trials and real-world reports have confirmed that PD-L1 status is a key factor for the successful use of immunotherapy in NSCLC, by predicting clinical outcomes and identifying patients most likely to …

Ivonescimab significantly improved PFS compared with pembrolizumab in previously untreated patients with advanced PD-L1 positive non-small cell lung cancer. Therefore, ivonescimab might represent another treatment option in the first-line setting for PD-L1-positive advanced non-small cell lung cancer.

Mar 12, 2025 · Background KRAS (Kirsten rat sarcoma viral oncogene homolog) gene mutation is one of the common driver gene mutations in non-small cell lung cancer (NSCLC) with poor prognosis. There are limited effective treatments for advanced NSCLC patients with KRAS mutation. This study aimed to evaluate the effectiveness of PD-1/L1 immune checkpoint inhibitors (ICIs) as a first-line immunotherapy for ...